In today’s briefing:
- IDT Australia (IDT): Poised to Benefit from RNA and On-Shoring
- Starpharma Holdings (SPL AU): Ready to Fly High as Viraleze Anti-Viral Nasal Spray Relaunched in UK
- Shimadzu (7701 JP): Weak Yen Supports Guidance
IDT Australia (IDT): Poised to Benefit from RNA and On-Shoring
- DT Australia has a long track record as a manufacturer of pharmaceutical drugs, including both active pharmaceutical ingredients (API) and finished drug products at its facilities in Melbourne.
- However, over the past decade it has been squeezed by cheaper overseas manufacturers.
- IDT reported its first operating profit for a decade in FY21, supported by a Covid-related Sterile Readiness government contract to recommission its sterile manufacturing facilities that could be used to manufacture a commercial Covid-19 vaccine, if required.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.
Starpharma Holdings (SPL AU): Ready to Fly High as Viraleze Anti-Viral Nasal Spray Relaunched in UK
- Starpharma Holdings (SPL AU) is an emerging biopharma company. The company has commercialized its flagship product Viraleze antiviral nasal spray in March 2021. It is now registered in 30+ countries.
- On June 30, Starpharma announced the relaunch of Viraleze in UK, one-year after its sales were paused temporarily in June 2021, thereby removing a major overhang on the share prices.
- Viraleze has shown strong potential to inactivate a broad spectrum of respiratory/cold viruses, including multiple variants of SARS-CoV-2 and influenza A and B.
Shimadzu (7701 JP): Weak Yen Supports Guidance
- The weak yen should add several billion to operating profit this fiscal year, helping the company meet or exceed guidance.
- Medical Systems, which were once barely profitable, generated a 9.1% operating margin last year due to growing service revenues and a better product mix.
- The share price should continue to hold up in a declining market.
Before it’s here, it’s on Smartkarma
